Related Experiment Video

Updated: Jul 15, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful?

Natale D'Alessandro1, Paola Poma, Giuseppe Montalto

  • 1Department of Pharmacological Sciences, University of Palermo, Via del Vespro 129, Palermo 90127, Italy. dalessan@unipa.it

World Journal of Gastroenterology
|May 1, 2007
PubMed

Insights

Hepatocellular carcinoma (HCC) drug resistance stems from overexpressed transporters, survival proteins (Inhibitory of Apoptosis Proteins), and activated NF-kappaB. Plant polyphenols may overcome this resistance, improving HCC treatment outcomes.

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Cancer biology
  • Pharmacology

Background:

  • Primary hepatocellular carcinoma (HCC) is a prevalent cancer with high mortality.
  • Current drug therapies for HCC often show limited efficacy.
  • Understanding the biological basis of HCC therapeutic resistance is crucial for developing new treatments.

Purpose of the Study:

  • To examine the mechanisms underlying therapeutic resistance in HCC.
  • To explore the role of pharmacological factors and cell survival pathways in HCC treatment failure.
  • To evaluate the potential of natural compounds in overcoming HCC drug resistance.

Main Methods:

  • Review of existing evidence on HCC drug resistance mechanisms.
  • Analysis of the involvement of drug transporters, detoxification enzymes, and Inhibitory of Apoptosis Proteins (IAPs).
  • Investigation of the role of transcription factors, such as NF-kappaB, in regulating resistance pathways.

Main Results:

  • Overexpression of drug transporters and detoxification enzymes contributes to HCC resistance.
  • Altered Inhibitory of Apoptosis Proteins (IAPs) enhance cell survival and proliferation, promoting resistance.
  • Activation of transcription factors like NF-kappaB can simultaneously upregulate these resistance mechanisms.

Conclusions:

  • Pharmacological mechanisms and altered cell survival pathways are key drivers of HCC therapeutic resistance.
  • Natural multi-targeted agents, such as plant polyphenols, show promise for sensitizing HCC to existing treatments.
  • Targeting these resistance mechanisms offers potential new strategies for improving HCC patient outcomes.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...